Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to identify certain markers in patients that could predict potential side effects from a type of cancer treatment called immune checkpoint inhibitors (ICPI). These treatments help the immune system fight cancer, but they can sometimes cause serious problems, known as immune-related adverse events (irAEs), which can affect organs like the intestines, liver, skin, and thyroid. By understanding which patients are more likely to experience these side effects, doctors can better manage treatment and improve safety.

To participate in this study, individuals must be at least 18 years old, have cancer, and be receiving ICPI treatment at specific hospitals in the Amiens-Picardie area. Participants will need to sign a consent form after being fully informed about the study. The trial is currently recruiting and aims to help future patients by finding ways to identify those at risk for these serious side effects early on. If you're eligible and decide to join, you'll be helping advance our understanding of how to make cancer treatments safer and more effective for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient with cancer, whatever initial tumoral histology and disease stage under ICPI treatment (anti-PD1 and/or anti-CTLA-4)
• • age \> 18
• • followed in oncology, pneumology, dermatology, gastroenterology departments of Amiens-Picardie University Hospital or Saint Quentin hospital
• • who received verbal and written information, and signed the consent form for the study
• Exclusion Criteria:
• • non ICPI treated patients
• • patient who received a first line of ICPI treatment
• • patient who received or is receiving MEK inhibitors as a treatment (because of possible lower response to ICPI treatment when associated)